35
Views
0
CrossRef citations to date
0
Altmetric
Editorial

The Potential of Exome Sequencing of Paired Colorectal Tumors and Synchronous Liver Metastases to Improve Treatment

ORCID Icon, ORCID Icon & ORCID Icon
Pages 697-699 | Received 18 Aug 2023, Accepted 18 Aug 2023, Published online: 28 Sep 2023

References

  • Sung H , FerlayJ , SiegelRLet al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin.71(3), 209–249 (2021).
  • Biller LH , SchragD. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA325(7), 669–685 (2021).
  • Siegel RL , WagleNS , CercekA , SmithRA , JemalA. Colorectal cancer statistics, 2023. CA Cancer J. Clin.73(3), 233–254 (2023).
  • Benson AB , VenookAP , Al-HawaryMMet al. Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology. JNCCN19(3), 329–359 (2021).
  • Zhang Y , DoranC , LeTKet al. Adverse events and clinical outcomes in patients treated with PD-(L)1 blockade for advanced non-small-cell lung cancer. Future Oncol.18(40), 4509–4523 (2022).
  • Siriwardena AK , MasonJM , MullamithaS , HancockHC , JegatheeswaranS. Management of colorectal cancer presenting with synchronous liver metastases. Nat. Rev. Clin. Oncol.11(8), 446–459 (2014).
  • Yamashita S , BrudvikKW , KopetzSEet al. Embryonic origin of primary colon cancer predicts pathologic response and survival in patients undergoing resection for colon cancer liver metastases. Ann. Surg.267(3), 514–520 (2018).
  • Colloca GA , VenturinoA , GuarneriD. Different variables predict the outcome of patients with synchronous versus metachronous metastases of colorectal cancer. Clin. Transl. Oncol.22(8), 1399–1406 (2020).
  • Slesser AA , GeorgiouP , BrownG , MudanS , GoldinR , TekkisP. The tumour biology of synchronous and metachronous colorectal liver metastases: a systematic review. Clin. Exp. Metastasis30(4), 457–470 (2013).
  • Hoppener DJ , NieropPMH , Van AmerongenMJet al. The disease-free interval between resection of primary colorectal malignancy and the detection of hepatic metastases predicts disease recurrence but not overall survival. Ann. Surg. Oncol.26(9), 2812–2820 (2019).
  • Awad MM , LiuS , RybkinIIet al. Acquired resistance to KRAS(G12C) inhibition in cancer. N. Engl. J. Med.384(25), 2382–2393 (2021).
  • Aziz H , AhmedZ , LeeY , DrummG , SaifMW. A comprehensive review of management of colorectal liver mets in the current Era. Cancer Med. J.5(1), 46–57 (2022).
  • Lee SY , HaqF , KimDet al. Comparative genomic analysis of primary and synchronous metastatic colorectal cancers. PLOS One9(3), e90459 (2014).
  • Wei Q , YeZ , ZhongXet al. Multiregion whole-exome sequencing of matched primary and metastatic tumors revealed genomic heterogeneity and suggested polyclonal seeding in colorectal cancer metastasis. Ann. Oncol.28(9), 2135–2141 (2017).
  • Sutton PA , JitheshPV , JonesRPet al. Exome sequencing of synchronously resected primary colorectal tumours and colorectal liver metastases to inform oncosurgical management. Eur. J. Surg. Oncol.44(1), 115–121 (2018).
  • Mogensen MB , RossingM , OstrupOet al. Genomic alterations accompanying tumour evolution in colorectal cancer: tracking the differences between primary tumours and synchronous liver metastases by whole-exome sequencing. BMC Cancer18(1), 752 (2018).
  • Shiomi A , KusuharaM , SuginoTet al. Comprehensive genomic analysis contrasting primary colorectal cancer and matched liver metastases. Oncol. Lett.21(6), 466 (2021).
  • Hlavac V , CervenkovaL , SusovaSet al. Exome sequencing of paired colorectal carcinomas and synchronous liver metastases for prognosis and therapy prediction. JCO Precis. Oncol.7, e2200557 (2023).
  • Horak J , KubecekO , SiskovaAet al. Differences in genome, transcriptome, miRNAome, and methylome in synchronous and metachronous liver metastasis of colorectal cancer. Front. Oncol.13, 1133598 (2023).
  • Mosele F , RemonJ , MateoJet al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann. Oncol.31(11), 1491–1505 (2020).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.